84
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Alnylam Pharmaceuticals's recently active trials. Comparator arms are excluded.
- Sterile Normal Saline (0.9% NaCl)15 trials
- Patisiran7 trials
- Lumasiran7 trials
- Zilebesiran5 trials
- Vutrisiran4 trials
- Givosiran4 trials
Upcoming readouts
Next primary completion dates among Alnylam Pharmaceuticals's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- May 2027A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusPhase 2
- Jun 2027HMBeacon: HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD …Phase 2
- Dec 2027TRITON-PN: TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary…Phase 3
- Apr 2028A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreate…Phase 2
- May 2030A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated A…Phase 2
- May 2030TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardio…Phase 3
Top therapeutic areas
Conditions studied most often across Alnylam Pharmaceuticals's recently active trials.
- TTR-mediated Amyloidosis8 trials
- Hypertension6 trials
- Acute Hepatic Porphyria5 trials
- Amyloidosis, Hereditary4 trials
- Primary Hyperoxaluria4 trials
- Type 2 Diabetes Mellitus (T2DM)3 trials
Alnylam Pharmaceuticals pipeline by phase
The main study drugs across 22 active trials Alnylam Pharmaceuticals leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 33 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Nucresiran | 2 | 2 | Dec 2027 est. | NCT07223203 · NCT07052903 |
| Vutrisiran | 2 | — | Mar 2028 est. | NCT06679946 · NCT04153149 |
| Zilebesiran | 1 | 1 | Sept 2030 est. | NCT07181109 |
Phase 25 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| ALN-4324 | 2 | 1 | May 2027 est. | NCT07465224 · NCT06845202 |
| ALN-6400 | 2 | 1 | Jun 2027 est. | NCT07575308 · NCT06659640 |
| ALN-APP | 2 | 1 | Aug 2027 est. | NCT06393712 · NCT05231785 |
| ALN-AGT01 RVR | 1 | 1 | Apr 2028 est. | NCT07553442 |
| Mivelsiran | 1 | 1 | May 2030 est. | NCT07636811 |
Phase 17 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| ALN-2232 | 1 | 1 | Apr 2027 est. | NCT07463846 |
| ALN-4285 | 1 | 1 | Dec 2026 est. | NCT07295717 |
| ALN-4915 | 1 | 1 | Jul 2027 est. | NCT07535606 |
| ALN-5288 | 1 | 1 | Mar 2030 est. | NCT07214727 |
| ALN-6222 | 1 | 1 | Dec 2027 est. | NCT07624071 |
| ALN-BCAT | 1 | 1 | Sept 2027 est. | NCT06600321 |
| ALN-HTT02 | 1 | 1 | Jul 2028 est. | NCT06585449 |
Derived from 22 active trials Alnylam Pharmaceuticals leads; 20 name an intervention, folding into 15 phased drugs. This is ComplyRx's reading of the registry, not Alnylam Pharmaceuticals's own pipeline disclosure.
Alnylam Pharmaceuticals trials
The 50 most significant of Alnylam Pharmaceuticals's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study to Evaluate ALN-4285 in Adult Healthy VolunteersNCT07295717ALN-4285 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 76 est. | 29 Dec 2026 |
| A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846ALN-2232 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 156 est. | 27 Apr 2027 |
| A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusNCT07465224ALN-4324 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 24 est. | 28 May 2027 |
| HMBeaconHMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMBNCT07575308ALN-6400 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 24 est. | 30 Jun 2027 |
| A Study to Evaluate ALN-4915 in Adult Healthy VolunteersNCT07535606ALN-4915 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 44 est. | 31 Jul 2027 |
| cAPPricorn-1A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyNCT06393712ALN-APP | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 210 est. | 9 Aug 2027 |
| A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMNCT06845202ALN-4324 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 105 est. | 31 Aug 2027 |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular CarcinomaNCT06600321ALN-BCAT | Phase 1 | Locked · track to reveal | OngoingRecruiting | 158 est. | 30 Sept 2027 |
| A Study to Evaluate ALN-6222 in Participants With ObesityNCT07624071ALN-6222 | Phase 1 | Not yet scored | OngoingRecruiting | 88 est. | 14 Dec 2027 |
| Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With PolyneuropathyNCT06360289 | — | Not yet scored | OngoingActive, not recruiting | 346 est. | 15 Dec 2027 |
| TRITON-PNTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With PolyneuropathyNCT07223203Nucresiran | Phase 3 | Locked · track to reveal | OngoingRecruiting | 125 est. | 27 Dec 2027 |
| InsigHHTA Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)NCT06659640ALN-6400 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 89 est. | 5 Jan 2028 |
| A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyNCT06679946Vutrisiran | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 700 est. | 31 Mar 2028 |
| A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With ZilebesiranNCT07553442ALN-AGT01 RVR | Phase 2 | Locked · track to reveal | OngoingRecruiting | 93 est. | 1 Apr 2028 |
| A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's DiseaseNCT06585449ALN-HTT02 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 66 est. | 5 Jul 2028 |
| BONAPH1DEBONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)NCT04982393 | — | Not yet scored | OngoingActive, not recruiting | 207 est. | 2 Jan 2029 |
| A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOADNCT05231785ALN-APP | Phase 1 | Locked · track to reveal | OngoingRecruiting | 60 est. | 20 Apr 2029 |
| A Study to Evaluate ALN-5288 in Patients With Alzheimer's DiseaseNCT07214727ALN-5288 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 50 est. | 6 Mar 2030 |
| A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)NCT07636811Mivelsiran | Phase 2 | Not yet scored | OngoingRecruiting | 58 est. | 18 May 2030 |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With CardiomyopathyNCT07052903Nucresiran | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,750 est. | 28 May 2030 |
| ZENITHZilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109Zilebesiran | Phase 3 | Locked · track to reveal | OngoingRecruiting | 11,000 est. | 30 Sept 2030 |
| Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance ProgramNCT05040373 | — | Not yet scored | OngoingRecruiting | 10 est. | 12 Oct 2030 |
| DemonsTTRateDemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World SettingNCT07358078 | — | Locked · track to reveal | OngoingRecruiting | 2,000 est. | 23 Oct 2030 |
| ELEVATEELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)NCT04883905 | — | Not yet scored | OngoingRecruiting | 150 est. | 31 Dec 2030 |
| ConTTRibuteConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)NCT04561518 | — | Locked · track to reveal | OngoingRecruiting | 1,500 est. | 31 Dec 2033 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy SubjectsNCT05661916ALN-TTRSC04 | Phase 1 | Locked · track to reveal | Completed | 96 est. | 30 Sept 2025 |
| A Study to Evaluate ALN-AGT01 RVR in Adult Healthy VolunteersNCT06675565ALN-AGT01 RVR | Phase 1 | Locked · track to reveal | Completed | 42 est. | 8 Sept 2025 |
| A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate HypertensionNCT06423352Zilebesiran | Phase 1 | Locked · track to reveal | Completed | 36 est. | 17 Jul 2025 |
| KARDIA-3Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)NCT06272487Zilebesiran | Phase 2 | Locked · track to reveal | Completed | 375 est. | 19 Jun 2025 |
| A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DMNCT05761301ALN-KHK | Phase 1 | Locked · track to reveal | StoppedTerminated | 49 est. | 3 Apr 2025 |
| HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With CardiomyopathyNCT04153149Vutrisiran | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 655 est. | 8 May 2024 |
| KARDIA-2Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)NCT05103332Indapamide | Phase 2 | Locked · track to reveal | Completed | 663 est. | 11 Dec 2023 |
| KARDIA-1A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate HypertensionNCT04936035ALN-AGT01 | Phase 2 | Locked · track to reveal | Completed | 394 est. | 4 Apr 2023 |
| An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1NCT03350451Lumasiran | Phase 2 | Locked · track to reveal | Completed | 20 est. | 7 Feb 2023 |
| A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With GoutNCT05256810ALN-XDH | Phase 1 | Locked · track to reveal | StoppedTerminated | 44 est. | 25 Jan 2023 |
| A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)NCT04565717ALN-HSD | Phase 1 | Locked · track to reveal | StoppedTerminated | 6 est. | 6 Jan 2023 |
| The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)NCT02510261Patisiran | Phase 3 | Locked · track to reveal | Completed | 211 est. | 23 Nov 2022 |
| A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate LevelsNCT05161936Lumasiran | Phase 2 | Locked · track to reveal | StoppedTerminated | 2 est. | 1 Nov 2022 |
| APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)NCT03997383Patisiran | Phase 3 | Locked · track to reveal | Completed | 360 est. | 20 Jun 2022 |
| A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A MutationNCT04201418Patisiran | — | Not yet scored | Completed | 67 est. | 24 May 2022 |
| A Study to Evaluate ALN-AGT01 in Patients With HypertensionNCT03934307ALN-AGT01 | Phase 1 | Locked · track to reveal | Completed | 124 est. | 20 Apr 2022 |
| A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)NCT03841448Cemdisiran | Phase 2 | Locked · track to reveal | StoppedTerminated | 31 est. | 17 Mar 2022 |
| A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)NCT02949830Givosiran | Phase 1 | Locked · track to reveal | Completed | 16 est. | 5 Nov 2021 |
| ILLUMINATE-CA Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1NCT04152200Lumasiran | Phase 3 | Locked · track to reveal | Completed | 21 est. | 18 May 2021 |
| EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)NCT02240784 | — | Not yet scored | Completed | 136 est. | 26 Apr 2021 |
| HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)NCT03759379Patisiran | Phase 3 | Locked · track to reveal | Completed | 164 est. | 10 Nov 2020 |
| Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver TransplantNCT03862807Patisiran | Phase 3 | Locked · track to reveal | Completed | 24 est. | 6 Oct 2020 |
| ILLUMINATE-BA Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1NCT03905694Lumasiran | Phase 3 | Locked · track to reveal | Completed | 18 est. | 29 Jun 2020 |
| A Study of ALN-AAT02 in Healthy Participants and Participants With ZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseNCT03767829ALN-AAT02 | Phase 1 | Locked · track to reveal | StoppedTerminated | 32 est. | 25 Jun 2020 |
| A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) DiseaseNCT03774784 | — | Not yet scored | StoppedTerminated | 26 est. | 18 May 2020 |